San
Francisco, 10 April , Lung
Cancer Diagnostics Market Analysis By Type (Small Cell Lung Cancer, Non-small
Cell Lung Cancer), By Test (Imaging Test, Biopsy, Sputum Cytology, Molecular
Testing), And Segment Forecasts To 2024.
The global lung cancer diagnostics market is
expected to reach USD 3,644.6 million by 2024, according to a new report by
Grand View Research Inc. The development of lung cancer-specific biomarkers is
one of the primary factors for the growth of the lung cancer diagnostics market
over the forecast period. These diagnostic tools facilitate the personalized
treatment approach of lung malignancies.
Various
biomarkers are present in the research pipeline. For instance, in November
2015, Epigenomics AG announced the launch of a new blood-based test using DNA
methylation biomarkers, the development of which is underway. The initial
results of this test revealed a promising outcome in the early diagnosis of
lung cancer.
Furthermore,
various awareness programs focusing on lung cancer and its associated symptoms
are initiated in an attempt to elevate the screening and diagnosis rates
inindividuals at a high risk of developing lung malignancies. For instance,
November is considered as a lung cancer awareness month across the UK, which is
supported by the Roy Castle Lung Cancer Foundation.
Access Full
Research Report On Lung Cancer Diagnostics Market Analysis:
Further key findings from the study suggest:
·
The small cell lung cancer
segment accounted for around 15% market share in 2015. This is an aggressive
subtype of the lung malignancies, which has proven to be fatal within a short
period of time if left undiagnosed.
·
Non-small cell lung cancer was
identified as the largest segment in 2015 with revenue of over USD 1,300.0
million. This is majorly due to the availability of novel lung cancer
diagnostics that facilitate the detection of large tumor growths.
·
The imaging tests segment was
identified as the largest revenue generating segment in 2015 with a market
share of around 50%. Major factors responsible for the large market share
include the frequent use of various imaging techniques such as CT scan, X-ray,
and MRI in the detection of lung malignancies coupled with the increased
availability of the diagnostic tools.
·
The molecular testing segment
is expected to grow at a profitable rate of around 10% over the forecast
period. The introduction of novel molecular testing techniques coupled with the
increasing number of investments to support the research and development
efforts for the development of biomarker-based molecular testing in lung cancer
detection is expected to foster the demand of this segment over the forecast period.
·
In 2015, North America
accounted for the largest revenue share of over 30% majorly due to supportive
government policies in the region coupled with the availability of
technology-enabled lung cancer diagnostics
·
Asia Pacific region is expected
to reach a revenue share of over 28% by 2024. Major factors responsible for the
growth include the constantly improving healthcare infrastructure, the growing
awareness of the disease symptoms, and a wide base of unmet clinical needs in
the developing countries in the region.
·
Major players of this market
include bioMérieux, Roche Diagnostics, Qiagen N.V., Illumina Inc., Thermo
Fisher Scientific, Agilent Technologies, Janssen, AstraZeneca plc, and Sanofi
S.A.
·
Novel product launches in the
lung cancer diagnostics product portfolio is one of the major strategic
initiatives adopted by the market players. For instance, Orion genomics is
involved in the development of novel biomarkers for lung cancer diagnosis.
Allegro Diagnostics is involved in the development and commercialization of
pulmonary genomics-based lung cancer diagnostics.
Browse More Reports Of This Category By
Grand View Research At: https://www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has
segmented the global lung cancer diagnostics market on the basis of type, test,
and region:
Global
Lung Cancer Diagnostics Type Outlook (Revenue, USD Million, 2016 - 2024)
·
Small Cell Lung Cancer
·
Non-small Cell Lung Cancer
Global
Lung Cancer Diagnostics Test Outlook (Revenue, USD Million, 2016 - 2024)
·
Imaging Test
·
Biopsy
·
Sputum Cytology
·
Molecular Test
·
Others
Lung
Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2016 - 2022)
·
North America
o
U.S.
o
Canada
·
Europe
o
Russia
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
MEA
o
South Africa
Access Full
Press Release of this Report: https://www.grandviewresearch.com/press-release/global-lung-cancer-diagnostics-market
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more
information: www.grandviewresearch.com/
No comments:
Post a Comment